Insider Trading March 5, 2026

Saba Capital Disposes of 253,128 ECAT Shares in Two Trades, Raising $3.78M

Ten percent holder reduces position across March 3-4, while ECAT continues to yield a high dividend

By Marcus Reed ECAT
Saba Capital Disposes of 253,128 ECAT Shares in Two Trades, Raising $3.78M
ECAT

Saba Capital Management, L.P., a 10% holder of BlackRock ESG Capital Allocation Term Trust (ECAT), reported the sale of 253,128 common shares in two transactions on March 3 and March 4, 2026, generating $3.78 million. The trades were executed at prices between $14.92 and $15.01 per share. After the sales, Saba’s holdings declined from 22,949,058 to 22,870,480 shares. ECAT currently trades at $14.83 and has a market capitalization of $1.47 billion. The trust carries a reported dividend yield of 22.13% and a one-year return of 10%, according to InvestingPro Tips.

Key Points

  • Saba Capital sold 253,128 ECAT shares in two trades on March 3 and March 4, 2026, for total proceeds of $3.78 million.
  • Sale prices ranged from $14.92 to $15.01 per share; ECAT was trading at $14.83 with a $1.47 billion market cap at the time of reporting.
  • InvestingPro Tips reports a 22.13% dividend yield for ECAT and a 10% return over the past year.

Saba Capital Management, L.P. disclosed two separate stock sales of BlackRock ESG Capital Allocation Term Trust (EXCHANGE: ECAT) shares on March 3 and March 4, 2026. The asset manager, identified as owning ten percent of ECAT, sold a total of 253,128 common shares across the two trades for aggregate proceeds of $3.78 million.

The initial transaction on March 3, 2026, consisted of 174,550 shares sold at $14.92 per share. Following that trade, Saba Capital reported holding 22,949,058 shares. On March 4, 2026, the firm sold an additional 78,578 shares at $15.01 per share, after which its reported stake stood at 22,870,480 shares.

Taken together, the two transactions were executed at prices ranging from $14.92 to $15.01 per share, yielding total proceeds of $3.78 million. At the time of the report, ECAT was trading at $14.83, a fraction below the sale prices, and the trust had a market capitalization of $1.47 billion.

Additional data noted from InvestingPro Tips highlights that ECAT currently pays a significant dividend, quoted at a 22.13% yield. The platform also reports that the stock delivered a 10% return over the past year. InvestingPro advertises that users can access four more ProTips and a broader set of financial metrics on its service.

The disclosure of these sales provides a precise record of Saba Capital’s trading activity in ECAT on those dates. No further commentary, motives, or forward-looking statements were included in the filing details provided.


Quick facts

  • Seller: Saba Capital Management, L.P. (10% owner)
  • Security: BlackRock ESG Capital Allocation Term Trust (EXCHANGE: ECAT)
  • Shares sold: 253,128 (174,550 on March 3; 78,578 on March 4, 2026)
  • Sale prices: $14.92 - $15.01 per share
  • Proceeds: $3.78 million
  • Post-sale holdings: 22,870,480 shares
  • Current trade price: $14.83; Market cap: $1.47 billion
  • Reported dividend yield: 22.13%; One-year return: 10% (InvestingPro Tips)

Risks

  • The disclosed sales reflect a reduction in holdings by a ten percent owner - this transaction could affect investor perception of the trust’s shares.
  • ECAT's current trading price is slightly below the recent sale prices, which may indicate short-term market pressure or price fluctuation risk.
  • Relying on external services for additional metrics (InvestingPro Tips) highlights dependency on third-party data providers for dividend and performance figures.

More from Insider Trading

Farmers National Banc Director Adds $15,892 in Shares as Bank Completes Middlefield Deal Mar 5, 2026 Vicor Director Sells $250K in Shares, Exercises Options the Same Day Mar 5, 2026 Clean Harbors Executive Chairman Sells $29.26M in Stock as Company Nears 52-Week High Mar 5, 2026 Sylvamo SVP Rodrigo Davoli Sells $150,995 in Company Stock; Q4 2025 Results Beat Estimates Mar 5, 2026 Ligand Director Executes Share Sale and Option Exercise Amid Strong Earnings and Analyst Support Mar 5, 2026